This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanacker, N. J. Articles by Kips, J. C. Search for Related Content PubMed PubMed Citation Articles by Vanacker, N. J. Articles by Kips, J. C.

Effect of Combining Salmeterol and Fluticasone on the Progression of Airway Remodeling

Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium

Correspondence and requests for reprints should be addressed to Nele Vanacker, B.Pharm., Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. E-mail: Nele.Vanacker{at}barclab.com

ABSTRACT

In subjects insufficiently controlled with low to moderate doses of inhaled corticosteroids, adding ß-agonists is clinically more beneficial than increasing the dose of inhaled corticosteroids. In the present study, we investigated the effect of adding salmeterol to fluticasone on allergen-induced airway inflammation and remodeling. Sensitized rats, in which characteristics of remodeling had been induced by ovalbumin exposure every 2 days from Days 14 to 28, were further exposed to ovalbumin or PBS from Days 29 to 42. During the last 2 weeks, before allergen exposure, rats were treated with aerosolized fluticasone propionate (10 mg), salmeterol (1 mg), salmeterol (1 mg) plus fluticasone propionate (10 mg), or placebo. After 4 weeks of ovalbumin exposure, the airways showed inflammatory changes, goblet cell hyperplasia, and enhanced fibronectin and collagen deposition. Salmeterol in monotherapy decreased bronchoalveolar lavage fluid eosinophil number but had no influence on structural changes. Combining salmeterol with fluticasone propionate counteracted goblet cell hyperplasia, but increased the amount of fibronectin and collagen in the airway wall. These effects of salmeterol did not influence airway responsiveness. We conclude that the combination of salmeterol and fluticasone propionate enhances aspects of allergen-induced airway remodeling. This is not accompanied by changes in airway responsiveness.

Key Words: asthma • corticosteroids • long-acting ß-agonists • remodeling • salmeterol

This article has been cited by other articles:

				A. M. Misior, H. Yan, R. M. Pascual, D. A. Deshpande, R. A. Panettieri, and R. B. Penn Mitogenic Effects of Cytokines on Smooth Muscle Are Critically Dependent on Protein Kinase A and Are Unmasked by Steroids and Cyclooxygenase Inhibitors Mol. Pharmacol., February 1, 2008; 73(2): 566 - 574. [Abstract] [Full Text] [PDF]

				E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]

				H. W. Chu, J. G. Rino, R. B. Wexler, K. Campbell, R. J. Harbeck, and R. J. Martin Mycoplasma pneumoniae infection increases airway collagen deposition in a murine model of allergic airway inflammation Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L125 - L133. [Abstract] [Full Text] [PDF]

				R. Tomic, C. C. Lassiter, J. D. Ritzenthaler, H. N. Rivera, and J. Roman Anti-Tissue Remodeling Effects of Corticosteroids: Fluticasone Propionate Inhibits Fibronectin Expression in Fibroblasts Chest, January 1, 2005; 127(1): 257 - 265. [Abstract] [Full Text] [PDF]

				P.E. Christie, M. Jonas, C-H. Tsai, E.Y. Chi, and W.R. Henderson Jr Increase in laminin expression in allergic airway remodelling and decrease by dexamethasone Eur. Respir. J., July 1, 2004; 24(1): 107 - 115. [Abstract] [Full Text] [PDF]

				V. Brusasco and R. Pellegrino Invited Review: Complexity of factors modulating airway narrowing in vivo: relevance to assessment of airway hyperresponsiveness J Appl Physiol, September 1, 2003; 95(3): 1305 - 1313. [Abstract] [Full Text] [PDF]

				M. J. Holtzman Drug Development for Asthma Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 163 - 171. [Abstract] [Full Text] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]